Decade in Review: Pharmaceutical Sector Leads Health Care M&A; Biotech Rising

 

 IMMEDIATE RELEASE Sanford B. Steever, Editor
Steve Monroe, Editor
800-248-1668
203-846-6800
Fax: 203-846-8300
pressreleases@levinassociates.com

 

NORWALK, CT – March 1, 2012 – According to Deal Search Online, an Irving Levin Associates M&A database,  pharmaceutical M&A deals have totaled over  $630 billion dollars committed to the industry during the last 10 years. Pharma was the single most active sector of the health care industry in the decade’s health care M&A market. Large pharmaceutical companies, with their significant levels of cash flow, have also helped drive the biotechnology M&A market as big pharma searches for new drugs.

The five largest deals  in 2011 reported in the Pharmaceutical sector, according to Deal Search Online, are listed below.

 

Five Largest Pharmaceutical Deals Of 2011                                     Value               Quarter

  1. Takeda Pharmaceutical acquired Nycomed                                  $13.6 billion           Q2:11
  1. Teva Pharmaceutical acquired Cephalon                                       $6.8 billion            Q2:11
  1. Astellas acquired rights to kidney cancer drug                               $1.4 billion            Q1:11
  1. Eli Lilly acquired a diabetes collaboration                                      $1.2 billion            Q1:11
  1. Forest Labs acquired Clinical Data                                               $1.2 billion            Q1:11

In the past decade, biotech M&A activity has also been increasing. In 2011, deal volume and dollars committed remained strong. Although 2011 did not surpass 2009’s decade-high 193 deals, buyer confidence remains and the average price per deal has risen.

The five largest deals in the Biotech sector in 2011, according to Deal Search Online, are listed below.

 

Five Largest Biotechnology Deals Of 2011                           Value               Quarter          

  1. Gilead Sciences acquired Pharmasset                                   $11.0 billion           Q4:11
  1. H. Lundbeck acquired a CNS drug alliance                            $2.0 billion           Q4:11
  1. Vertex acquired two nucleotide drugs                                    $1.5 billion           Q2:11           
  1. Amylin acquired rights to a diabetes drug program                  $1.5 billion           Q4:11
  1. Alexion Pharmaceuticals acquired Enobia Pharma                  $1.1 billion           Q4:11

 

 For more information on DealSearchOnline.com or for a subscription to any Irving Levin publication, call 800-248-1668 or go to www.levinassociates.com.  Irving Levin Associates, Inc. was established in 1948 and is based in Norwalk, CT.  This privately held corporation publishes research reports and newsletters, and maintains health care and seniors housing M&A databases.   
 

Click here for more information on any of our publications.